A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid Tumors
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Enoblituzumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Acronyms basket
- Sponsors I-MAB Biopharma; TJ Biopharma
- 11 Apr 2024 Status changed from suspended to withdrawn prior to enrolment.
- 21 Feb 2023 Planned initiation date changed from 31 Dec 2022 to 31 Dec 2023.
- 21 Feb 2023 Status changed from recruiting to suspended due to company development strategy adjustment.